National Cancer Statistics: American College of Surgeons Cancer Programs Annual Report from 2022 Participant User File

Earlier this year, the American College of Surgeons Cancer Program published its first annual report from the NCDB 2021 adult participant user file including three cancers of focus: breast, pancreas, and colon.1 The current report follows with updated data from the NCDB 2022 adult participant user file and provides observations and trends of cancer diagnoses, patient demographics, and treatments as well as in depth reports on treatment and outcomes for three different cancer sites: esophageal cancer, melanoma, and prostate cancer. Of the 1,331,740 cancers diagnosed in 2022 at 1,250 reporting CoC hospitals, the NCDB's five most common adult cancers varied by sex. In men, the top five cancers in the 2022 NCDB PUF were Prostate, Lung (Bronchus-Non-Small Cell Carcinoma), Melanoma of the Skin, Urinary Bladder, and Colon; in women, they were Breast, Lung (Bronchus-Non-Small Cell Carcinoma), Corpus Uteri, Colon, and Melanoma of the Skin. Roughly half of patients with esophageal cancer presented with Stage IV disease in 2022. Most (70.5%) patients did not undergo surgical resection; for those who did, esophagectomy was most common. Increasing clinical stage group and grade were associated with poorer overall survival. Melanoma presents most often as stage 1 disease (68.1%). Among invasive melanomas, histology was most commonly superficial spreading melanoma (43.5%) with a primary tumor site in the skin of the trunk (30.3%) and upper limb and shoulder (25.1%). Increasing clinical stage and presence of ulceration were associated with poorer survival. Men with prostate cancer were most commonly diagnosed with Stage II disease. Most (61.5%) did not receive surgical treatment, but among those that did, the most common surgical procedure performed was prostatectomy (85.4%). Survival is most dependent on clinical stage, grade and prostate-specific antigen.